Abstract

TARGETING PROTON PUMP INHIBITORS TO COLON: AN OVERVIEW TO CHANGING SCENARIO

Dr. G. Selvi*, D. Jai sai, M. Keerthanasri, A. Mohammed Sajith, R. Srikaviya and T. Vidhya Lakshmi

ABSTRACT

This study aims to develop lansoprazole microspheres using the ionic gelation technique for targeted colon delivery and sustained release, specifically to address colon cancer. Lansoprazole, a proton pump inhibitor (PPI), is commonly used for gastrointestinal issues but has shown potential anti-cancer properties, particularly in colon cancer, by inhibiting cell growth and potentially enhancing the effectiveness of other treatments. The microspheres were formulated using lansoprazole and sodium alginate at ratios of 1:25 and 1:50. Preformulation studies, including organoleptic properties, solubility, FTIR compatibility analysis, and UV calibration curve, were conducted, with all results falling within acceptable limits. The microspheres were evaluated for percentage yield (77% to 88%), drug content (71% to 76%), and entrapment efficiency (83% to 98%), with additional SEM analysis and in vitro drug release studies conducted using the USP dissolution apparatus type 2 in 0.01N HCl and phosphate buffer pH 6.8. These parameters met the required standards. The results indicated that formulation F2 was the most promising. The release profile of lansoprazole from F2 was analyzed through curve fitting, which revealed that the best fit was a zero-order release model, with the drug release occurring via a combination of diffusion and dissolution mechanisms. Stability studies demonstrated no significant changes in drug content or dissolution rates, in line with ICH guidelines. Overall, the formulation shows a promising sustained-release profile for colon targeting in colorectal cancer.

Keywords: .